|
STABILITY AND PHARMACOKINETICS OF LJP
920, AN OCTAMERIC GAL (a1-3) GAL CONJUGATE
FOR INHIBITION OF XENOTRANSPLANTATION
REJECTION
Lee Jia, et al.
Presented at
The American Association of Pharmaceutical
Scientists (AAPS) Annual Meeting
New Orleans, Louisiana
Nov. 14-18, 1999
INDUCTION OF TOLERANCE TO GAL a(1,3) GAL
USING AN OCTAMERIC GAL a(1,3) GAL CONJUGATE,
LJP 920
Mary-Ann Campbell, et al.
Presented at
The 25th Annual Conference of the La Jolla
Immunologists
La Jolla, California
Nov. 8-9, 1999
DEVELOPMENT OF AN ANTIGEN-SPECIFIC B-CELL TOLERAGEN FOR THE TREATMENT
OF ANTIPHOSPHOLIPID SYNDROME
Keith Cockerill, et al.
Presented at
The 25th Annual Conference of the La Jolla
Immunologists
La Jolla, Califorina
Nov. 8-9, 1999
SINGLE POINT MUTATIONS IN DOMAIN 1 OF
ß2-GLYCOPROTEIN I DECREASE BINDING OF
ANTIPHOSPHOLIPID AUTOANTIBODIES
Eric M. Smith, et al.
Presented at
The 25th Annual Conference of the La Jolla
Immunologists, La Jolla, California
Nov. 8-9, 1999
INDUCTION OF TOLERANCE TO GAL a(1,3) GAL
USING AN OCTAMERIC GAL a(1,3) GAL CONJUGATE,
LJP920
Mary-Ann Campbell, et al.
Presented at
The 5th Congress of the International
Xenotransplantation Association
Nagoya, Japan
Oct 24-28, 1999
Also presented at
The IBC's 5th Annual Conference on Xenotransplantation
Dec. 6-7, 1999
EFFECT OF aGAL VALENCY IN THE INHIBITION
OF BINDING OF HUMAN ANTI-aGAL ANTIBODIES
Richard Jack, et al.
Presented at
The 5th Congress of the International
Xenotransplantation Association
Nagoya, Japan
Oct. 24-28, 1999
DEVELOPMENT OF A B CELL TOLERAGEN TO ELIMINATE
PRO-THROMBOTIC ANTIBODIES IN ANTIPHOSPHOLIPID
SYNDROME
Matthew D. Linnik. Presented at IBC's
10th Anniversary International Symposium
- AATD '99 (Advances in Anticoagulant,
Antithrombotic and Thrombolytic Drugs),
Oct. 3-7, 1999, Boston, MA.
DEVELOPMENT OF MULTIVALENT TOLERAGENS
TO INHIBIT BINDING OF HUMAN ANTI-GALACTOSE
a1,3 GALACTOSE ANTIBODIES
Lin Yu, et al.
Presented at
The 25th Annual Scientific Meeting of
the American Society of Transplant Surgeons,
Chicago, Illinois
May 19-21, 1999
ANTIPHOSPHOLIPID ANTIBODIES AGAINST DOMAIN
1 OF b2-GPI PROMOTE CLOTTING BY INHIBITING
THE INACTIVATION OF FACTOR VA
Matthew D. Linnik, et al.
Presented at
The 2nd International Congress on Autoimmunity
Tel Aviv, Israel
Mar. 7-12, 1999
ANTIPHOSPHOLIPID ANTIBODIES PROMOTE CLOTTING
BY INHIBITING THE INACTIVATION OF FACTOR
VA.
Matthew D. Linnik, et al.
Presented at
The Keystone Symposia on B Lymphocyte
Biology and Disease,
Taos, New Mexico
Feb. 8-14, 1999
TOWARDS
IDENTIFICATION OF A TOLERAGEN FOR THE
TREATMENT OF MYASTHENIA GRAVIS.
Mary-Ann Campbell, et al.
Presented at
The Keystone Symposium, B Lymphocyte
Biology and Disease
Taos, New Mexico
Feb. 8-14, 1999
|
ANTIBODY AFFINITIES AND RELATIVE TITERS
IN POLYCLONAL POPULATIONS: SURFACE PLASMON
RESONANCE ANALYSIS OF ANTI-DNA ANTIBODIES
Daniel S. Sem, et al.
Published in Archives of Biochemistry
and Biophysics, Vol. 372, No. 1, December
1, pp. 62-68, 1999.
MULTIVALENT
THIOETHER-PEPTIDE CONJUGATES: B CELL TOLERANCE
OF AN ANTI-PEPTIDE IMMUNE RESPONSE
David S. Jones, et al.
Published in Bioconjugate Chemistry, 1999,
10, 480-488.
APPLICATION OF FLUORESCENCE POLARIZATION
TO THE STEADY-STATE ENZYME KINETIC ANALYSIS
OF CALPAIN II
Daniel S. Sem, et al.
Published in Federation of European Biochemical Societies (FEBS
Letters) 443, 17-19, 1999.
|